SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Organovo Holdings, Inc. – ‘10-KT’ for 3/31/13 – ‘R6’

On:  Friday, 5/24/13, at 4:02pm ET   ·   For:  3/31/13   ·   Accession #:  1193125-13-235652   ·   File #:  0-54621

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/24/13  Organovo Holdings, Inc.           10-KT       3/31/13   66:7.4M                                   Donnelley … Solutions/FA

Annual-Transition Report   —   Form 10-K   —   Rule 13a-10 / 15d-10
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-KT       Annual-Transition Report                            HTML    783K 
 2: EX-23.1     Consent of Experts or Counsel                       HTML     18K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
43: R1          Document and Entity Information                     HTML     48K 
33: R2          Consolidated Balance Sheets                         HTML    129K 
41: R3          Consolidated Balance Sheets (Parenthetical)         HTML     33K 
46: R4          Consolidated Statements of Operations               HTML     83K 
61: R5          Consolidated Statements of Stockholders' Equity     HTML    134K 
                (Deficit)                                                        
35: R6          Consolidated Statements of Cash Flows               HTML    156K 
40: R7          Consolidated Statements of Cash Flows               HTML     47K 
                (Parenthetical)                                                  
30: R8          Change in Fiscal Year End                           HTML     22K 
22: R9          Description of Business and Summary of Significant  HTML     96K 
                Accounting Policies                                              
62: R10         Fixed Assets                                        HTML     37K 
48: R11         Accrued Expenses                                    HTML     29K 
47: R12         Derivative Liability                                HTML     49K 
52: R13         Convertible Notes Payable                           HTML     39K 
53: R14         Stockholders' Equity                                HTML    112K 
51: R15         Commitments and Contingencies                       HTML     44K 
54: R16         Licensing Agreements and Research Contracts         HTML     37K 
42: R17         Income Taxes                                        HTML     43K 
45: R18         Concentrations                                      HTML     26K 
50: R19         Subsequent Events                                   HTML     22K 
66: R20         Description of Business and Summary of Significant  HTML    191K 
                Accounting Policies (Policies)                                   
57: R21         Description of Business and Summary of Significant  HTML     49K 
                Accounting Policies (Tables)                                     
37: R22         Fixed Assets (Tables)                               HTML     35K 
49: R23         Accrued Expenses (Tables)                           HTML     28K 
39: R24         Derivative Liability (Tables)                       HTML     34K 
16: R25         Stockholders' Equity (Tables)                       HTML     91K 
58: R26         Commitments and Contingencies (Tables)              HTML     40K 
63: R27         Licensing Agreements and Research Contracts         HTML     28K 
                (Tables)                                                         
26: R28         Income Taxes (Tables)                               HTML     35K 
25: R29         Description of Business and Summary of Significant  HTML     32K 
                Accounting Policies (Details)                                    
28: R30         Description of Business and Summary of Significant  HTML     38K 
                Accounting Policies (Details 1)                                  
29: R31         Description of Business and Summary of Significant  HTML    283K 
                Accounting Policies (Details Textual)                            
31: R32         Fixed Assets (Details)                              HTML     41K 
15: R33         Fixed Assets (Details Textual)                      HTML     23K 
55: R34         Accrued Expenses (Details)                          HTML     34K 
36: R35         Derivative Liability (Details)                      HTML     34K 
38: R36         Derivative Liability (Details Textual)              HTML     39K 
19: R37         Convertible Notes Payable (Details)                 HTML    230K 
65: R38         Stockholders' Equity (Details)                      HTML     34K 
12: R39         Stockholders' Equity (Details 1)                    HTML     59K 
32: R40         Stockholders' Equity (Details 2)                    HTML     36K 
60: R41         Stockholders' Equity (Details 3)                    HTML     49K 
18: R42         Stockholders' Equity (Details 4)                    HTML     24K 
24: R43         Stockholders' Equity (Details Textual)              HTML    375K 
27: R44         Commitments and Contingencies (Details)             HTML     33K 
34: R45         Commitments and Contingencies (Details 1)           HTML     28K 
14: R46         Commitments and Contingencies (Details 2)           HTML     46K 
21: R47         Commitments and Contingencies (Details Textual)     HTML     34K 
13: R48         Licensing Agreements and Research Contracts         HTML     28K 
                (Details)                                                        
59: R49         Licensing Agreements and Research Contracts         HTML     83K 
                (Details Textual)                                                
17: R50         Income Taxes (Details)                              HTML     51K 
56: R51         Income Taxes (Details Textual)                      HTML     48K 
20: R52         Subsequent Events (Details Textual)                 HTML     29K 
64: XML         IDEA XML File -- Filing Summary                      XML    102K 
23: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.16M 
 6: EX-101.INS  XBRL Instance -- onvo-20130331                       XML   1.38M 
 8: EX-101.CAL  XBRL Calculations -- onvo-20130331_cal               XML    193K 
 9: EX-101.DEF  XBRL Definitions -- onvo-20130331_def                XML    623K 
10: EX-101.LAB  XBRL Labels -- onvo-20130331_lab                     XML   1.38M 
11: EX-101.PRE  XBRL Presentations -- onvo-20130331_pre              XML    981K 
 7: EX-101.SCH  XBRL Schema -- onvo-20130331                         XSD    201K 
44: ZIP         XBRL Zipped Folder -- 0001193125-13-235652-xbrl      Zip    160K

‘R6’   —   Consolidated Statements of Cash Flows

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
 3 Months Ended 12 Months Ended 71 Months Ended
Cash Flows From Operating Activities            
Net loss $ (16,120,000) $ (37,081,000) $ (43,553,000) $ (4,383,000) $ (1,339,000) $ (66,365,000)
Adjustments to reconcile net loss to net cash used in operating activities:            
Amortization of debt discount 0 896,000 896,200 603,800   2,084,000
Loss on disposal of fixed assets     158,000     158,000
Depreciation and amortization 80,000 17,000 195,000 68,000 59,000 431,000
Amortization of deferred financing costs   319,000 319,000 119,000   438,000
Amortization of warrants issued for services 261,000   556,000     817,000
Interest accrued on convertible notes payable   12,000 12,000 232,000   495,000
Warrants issued in connection with exchange agreement       528,000   528,000
Loss on inducement to exercise warrants     1,904,000     1,904,000
Expense associated with warrant modification 65,000         65,000
Stock-based compensation 848,000 4,000 1,435,000 9,000 4,000 2,300,000
Fair value of warrant liabilities in excess of proceeds   19,019,000 19,019,000     19,019,000
Change in fair value of warrant liabilities 12,034,000 13,506,000 9,931,000 7,000   21,972,000
Increase (decrease) in cash resulting from changes in:            
Grants receivable 61,000   (162,000) 60,000 (55,000) (101,000)
Inventory   (45,000) (459,000) (224,000) (68,000) (751,000)
Prepaid expenses and other current assets (61,000) (65,000) (101,000) (69,000) (2,000) (255,000)
Accounts payable 216,000 (217,000) (233,000) 373,000 230,000 641,000
Accrued expenses (201,000) (37,000) 543,000 132,000 83,000 780,000
Deferred revenue 62,000 116,000 (153,000) 46,000 107,000 62,000
Accrued interest         161,000  
Net cash used in operating activities (2,755,000) (3,556,000) (9,693,000) (1,914,000) (820,000) (15,778,000)
Cash Flows From Investing Activities            
Restricted cash deposits   (38,000) (88,000)     (88,000)
Purchases of fixed assets (137,000) (6,000) (357,000) (46,000) (48,000) (921,000)
Purchases of intangible assets (19,000)     (65,000) (5,000) (114,000)
Net cash used in investing activities (156,000) (44,000) (445,000) (111,000) (53,000) (1,123,000)
Cash Flows From Financing Activities            
Proceeds from issuance of convertible notes payable       2,543,000 992,000 4,630,000
Proceeds from issuance of common stock and exercise of warrants, net 3,724,000 13,723,000 24,714,000     28,438,000
Proceeds from exercise of stock options     18,000     18,000
Proceeds from issuance of related party notes payable       225,000 25,000 250,000
Repayment of related party notes payable       (250,000)   (250,000)
Repayment of convertible notes and interest payable   (110,000) (110,000)     (110,000)
Principal payments on capital lease obligations (2,000)   (7,000)     (9,000)
Deferred financing costs       (438,000)   (438,000)
Net cash provided by financing activities 3,722,000 13,613,000 24,615,000 2,080,000 1,017,000 32,529,000
Net Increase in Cash and Cash Equivalents 811,000 10,013,000 14,477,000 55,000 144,000 15,628,000
Cash and Cash Equivalents at Beginning of Period 14,817,000 340,000 340,000 285,000 141,000  
Cash and Cash Equivalents at End of Period 15,628,000 10,353,000 14,817,000 340,000 285,000 15,628,000
Supplemental Disclosures of Cash Flow Information:            
Interest   10,000 10,000     10,000
Income Taxes   $ 1,000 $ 1,000 $ 1,000 $ 1,000 $ 3,000

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-KT’ Filing    Date    Other Filings
Filed on:5/24/13
For Period end:3/31/138-K
12/31/1210-K
3/31/1210-Q
12/31/1110-Q
12/31/10
9/15/09
 List all Filings 
↑Top
Filing Submission 0001193125-13-235652   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 2, 4:35:49.1pm ET